Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Core One Labs Inc. C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan... see more

Recent & Breaking News (CSE:COOL)

Core One Labs' Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care

GlobeNewswire February 9, 2022

Core One Labs Subsidiary Akome Biotech signs Research Agreement with the University of Barcelona

John Ballem  January 26, 2022

Core One Labs' Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences

GlobeNewswire January 26, 2022

Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin

GlobeNewswire January 21, 2022

Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022

GlobeNewswire January 18, 2022

Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022

GlobeNewswire January 15, 2022

Core One Labs (CSE:COOL) receives Health Canada approval for DMT

Trevor Abes  January 10, 2022

Core One Labs Now Also Working to Biosynthesize DMT and Receives License

GlobeNewswire January 8, 2022

Core One Labs Applauds Health Canada's Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

GlobeNewswire January 5, 2022

Core One Labs (CSE:COOL) acquires New Path Laboratories

Trevor Abes  December 24, 2021

Core One Labs Acquires New Path Laboratories

GlobeNewswire December 23, 2021

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

GlobeNewswire October 16, 2021

Core One Labs Applauds TheraPsil on Its Submission to Health Canada

GlobeNewswire August 15, 2021

Core One Labs (CSE:COOL) submits psilocybin psychedelic-assisted therapy application

Simon Druker  August 13, 2021

Core One Labs' Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

GlobeNewswire August 13, 2021

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

GlobeNewswire August 7, 2021

Core One Labs' Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion

GlobeNewswire August 5, 2021

Core One's Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021

GlobeNewswire July 30, 2021

Core One Labs' Akome Seeks to Revolutionize Treatment of Parkinson's Disease and Submits Application to Protect IP

GlobeNewswire July 26, 2021

Core One Labs' Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

GlobeNewswire July 21, 2021